Two Israeli Pharmaceutical Companies Get Approvals from FDA

This month, two Israeli pharmaceutical companies received good news from the US Food and Drug Administration (FDA). Jerusalem’s Gamida Cell was granted orphan product development status for NiCord, its enriched stem-cell treatment for acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma and myelodysplastic syndrome. Orphan drug designation promotes the development of promising …